Table 2.
Evidence of genetic and functional involvement of complement in TA-TMA.
| Genetic Alterations in Complement Regulation (Positive Subjects/Investigated Subjects) | Anti-Factor H Auto-ab (Positive Subjects/Investigated Subjects) |
Complement Functional Involvement | ||
|---|---|---|---|---|
| Receiver’s DNA | Donor’s DNA | |||
| Mii et al. 2011 [23] | - | - | - | C4d glomerular deposition |
| Laskin et al. 2013 [24] | - | - | - | C4d glomerular deposition |
| Jodele et al. 2013 [30] | 5/6 | 1/6 | 3/6 | - |
| Jodele et al. 2014 [25] | - | - | - | Elevated plasma levels of sC5b-9 |
| Jodele et al. 2016 [32] | 22/34 | - | - | - |
| Ardissino et al. 2017 [35] | 0/16 | 6/16 | - | - |
| Qi et al. 2017 [26] | - | - | - | Elevated plasma levels of sC5b-9 and C3b |
| Gavriilaki et al. 2020 [28] | - | - | - | Elevated plasma levels of sC5b-9 |
| Gavriilaki et al. 2020 [33] | 31 */40 | 5 */18 | - | Elevated plasma levels of sC5b-9 |
| Mezo et al. 2020 [27] | - | - | - | Elevated plasma levels of sC5b-9 |
| Cugno et al. 2021 [31] | - | 4/20 | 7/20 | - |
| Rodriguez et al. 2021 [36] | 4/33 | 11/33 | - | - |
| Okamura et al. 2021 [29] | 9/15 | - | - | Elevated plasma levels of Ba |
| Zhang et al. 2021 [37] | 9 */91 | - | - | - |
* number of identified variants.